Coronavirus company news summary – Russia completes Covid-19 vaccine trials – Avigan failed to achieve statistical significance in Fujifilm trial

Allie Nawrat 13 July 2020 (Last Updated July 13th, 2020 08:48)

13 July 2020 

Russia has become the first country to have completed clinical trials of a Covid-19 vaccine candidate, after Sechenov University said that it had concluded its study. Data showed the vaccine candidate was effective, reported Russian news agency TASS. The participants will be discharged on 15 July and 20 July and will be monitored on an outpatient basis.

The Therapeutic Goods Administration (TGA) of Australia has awarded provisional approval for the use of Gilead Sciences’ remdesivir (Veklury) to treat Covid-19 patients, marking the first authorisation of a treatment for this disease in the country. The approval enables use of the drug in adults and adolescents hospitalised with severe Covid-19 symptoms.

Thailand is set to advance its Covid-19 vaccine candidate into clinical trials as early as September, after the vaccine demonstrated ability to generate antibodies in monkeys and mice, according to Bloomberg. Chulalongkorn University’s Center of Excellence in Vaccine Research and Development head researcher Kiat Ruxrungtham said that the vaccine could be available by the second half of next year, if human trials are successful.

A clinical trial performed by Japanese researchers has showed inconclusive data from Covid-19 patients treated with Fujifilm’s Avigan drug, reported Reuters. Fujita Health University researcher Yohei Doi said that the drug led to improvement in patients treated early, compared to those who received delayed doses, but failed to achieve statistical significance.

The University of Queensland in Australia has started dosing healthy adults in a Phase I clinical trial being conducted to assess the safety of its Covid-19 vaccine candidate, along with the ability to produce immune response. The study will recruit approximately 120 participants aged 18 to 55 years, and the first dose of the vaccine was given at Nucleus Network’s Brisbane clinic.